Moss, Steven J.; Bobardt, Michael; Leyssen, Pieter; Coates, Nigel; Chatterji, Udayan; Xie, Dejian; Foster, Teresa; Liu, Jinlun; Nur-e-Alam, Mohammad; Suthar, Dipen; Chen, Yongsheng; Warneck, Tony; Zhang, Ming-Qiang; Neyts, Johan; Gallay, Philippe; Wilkinson, Barrie; Gregory, Matthew A. published the artcile< Sangamides, a new class of cyclophilin-inhibiting host-targeted antivirals for treatment of HCV infection>, Category: amides-buliding-blocks, the main research area is sangamide cyclophilin inhibitor HCV antiviral.
Sangamides are amide derivatives of sanglifehrin A, a cyclophilin-binding polyketide natural product which is structurally distinct from cyclosporine A. Cyclosporine A is the starting point for the synthesis of cyclophilin inhibitors such as alisporivir, currently in development for the treatment of HCV infection. We report here initial results of the optimization program which led to identification of the sangamides, compounds that exhibit significantly improved potential for the treatment of chronic HCV infection.
MedChemComm published new progress about Antiviral agents. 5326-82-9 belongs to class amides-buliding-blocks, and the molecular formula is C10H20ClNO, Category: amides-buliding-blocks.
Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics